Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST

Luis M. Blanco-Colio, Jose L. Martín-Ventura, Eduardo De Teresa, Csaba Farsang, Allan Gaw, Gianfranco Gensini, Lawrence A. Leiter, Anatoly Langer, Pierre Martineau, Gonzalo Hérnandez, Jesús Egido

Research output: Contribution to journalArticle

Abstract

OBJECTIVES - Increasing evidence indicates that the Fas/Fas ligand interaction is involved in atherogenesis. We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment. METHODS AND RESULTS - ACTFAST was a 12-week, prospective, multicenter, open-label trial which enrolled subjects (statin-free or statin-treated at baseline) with coronary heart disease (CHD), CHD-equivalent, or 10-year CHD risk >20%. Subjects with LDL-C between 100 to 220 mg/dL (2.6 to 5.7 mmol/L) and triglycerides ≤600 mg/dL (6.8 mmol/L) were assigned to a starting dose of atorvastatin (10 to 80 mg/d) based on LDL-C at screening. Of the 2117 subjects enrolled in ACTFAST, AIM sub-study included the 1078 statin-free patients. At study end, 85% of these subjects reached LDL-C target. Mean sFas levels were increased and sFasL were reduced in subjects at high cardiovascular risk compared with healthy subjects. Atorvastatin reduced sFas in the whole population as well as in patients with metabolic syndrome or diabetes. Minimal changes were observed in sFasL. CONCLUSIONS - sFas concentrations are increased and sFasL are decreased in subjects at high cardiovascular risk, suggesting that these proteins may be novel markers of vascular injury. Atorvastatin reduces sFas, indicating that short-term treatment with atorvastatin exhibits antiinflammatory effects in these subjects.

Original languageEnglish
Pages (from-to)168-174
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Fas Ligand Protein
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Disease
Vascular System Injuries
Atorvastatin Calcium
Atherosclerosis
Healthy Volunteers
Triglycerides
Anti-Inflammatory Agents
Therapeutics
Population
oxidized low density lipoprotein
Proteins

Keywords

  • Atorvastatin
  • C-reactive protein
  • Inflammation
  • Soluble Fas
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Increased soluble Fas plasma levels in subjects at high cardiovascular risk : Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST. / Blanco-Colio, Luis M.; Martín-Ventura, Jose L.; De Teresa, Eduardo; Farsang, Csaba; Gaw, Allan; Gensini, Gianfranco; Leiter, Lawrence A.; Langer, Anatoly; Martineau, Pierre; Hérnandez, Gonzalo; Egido, Jesús.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, No. 1, 01.2007, p. 168-174.

Research output: Contribution to journalArticle

Blanco-Colio, LM, Martín-Ventura, JL, De Teresa, E, Farsang, C, Gaw, A, Gensini, G, Leiter, LA, Langer, A, Martineau, P, Hérnandez, G & Egido, J 2007, 'Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 168-174. https://doi.org/10.1161/01.ATV.0000250616.26308.d7
Blanco-Colio, Luis M. ; Martín-Ventura, Jose L. ; De Teresa, Eduardo ; Farsang, Csaba ; Gaw, Allan ; Gensini, Gianfranco ; Leiter, Lawrence A. ; Langer, Anatoly ; Martineau, Pierre ; Hérnandez, Gonzalo ; Egido, Jesús. / Increased soluble Fas plasma levels in subjects at high cardiovascular risk : Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2007 ; Vol. 27, No. 1. pp. 168-174.
@article{3004128821d84befa7cebf3ac3a94ee2,
title = "Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST",
abstract = "OBJECTIVES - Increasing evidence indicates that the Fas/Fas ligand interaction is involved in atherogenesis. We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment. METHODS AND RESULTS - ACTFAST was a 12-week, prospective, multicenter, open-label trial which enrolled subjects (statin-free or statin-treated at baseline) with coronary heart disease (CHD), CHD-equivalent, or 10-year CHD risk >20{\%}. Subjects with LDL-C between 100 to 220 mg/dL (2.6 to 5.7 mmol/L) and triglycerides ≤600 mg/dL (6.8 mmol/L) were assigned to a starting dose of atorvastatin (10 to 80 mg/d) based on LDL-C at screening. Of the 2117 subjects enrolled in ACTFAST, AIM sub-study included the 1078 statin-free patients. At study end, 85{\%} of these subjects reached LDL-C target. Mean sFas levels were increased and sFasL were reduced in subjects at high cardiovascular risk compared with healthy subjects. Atorvastatin reduced sFas in the whole population as well as in patients with metabolic syndrome or diabetes. Minimal changes were observed in sFasL. CONCLUSIONS - sFas concentrations are increased and sFasL are decreased in subjects at high cardiovascular risk, suggesting that these proteins may be novel markers of vascular injury. Atorvastatin reduces sFas, indicating that short-term treatment with atorvastatin exhibits antiinflammatory effects in these subjects.",
keywords = "Atorvastatin, C-reactive protein, Inflammation, Soluble Fas, Statins",
author = "Blanco-Colio, {Luis M.} and Mart{\'i}n-Ventura, {Jose L.} and {De Teresa}, Eduardo and Csaba Farsang and Allan Gaw and Gianfranco Gensini and Leiter, {Lawrence A.} and Anatoly Langer and Pierre Martineau and Gonzalo H{\'e}rnandez and Jes{\'u}s Egido",
year = "2007",
month = "1",
doi = "10.1161/01.ATV.0000250616.26308.d7",
language = "English",
volume = "27",
pages = "168--174",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Increased soluble Fas plasma levels in subjects at high cardiovascular risk

T2 - Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST

AU - Blanco-Colio, Luis M.

AU - Martín-Ventura, Jose L.

AU - De Teresa, Eduardo

AU - Farsang, Csaba

AU - Gaw, Allan

AU - Gensini, Gianfranco

AU - Leiter, Lawrence A.

AU - Langer, Anatoly

AU - Martineau, Pierre

AU - Hérnandez, Gonzalo

AU - Egido, Jesús

PY - 2007/1

Y1 - 2007/1

N2 - OBJECTIVES - Increasing evidence indicates that the Fas/Fas ligand interaction is involved in atherogenesis. We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment. METHODS AND RESULTS - ACTFAST was a 12-week, prospective, multicenter, open-label trial which enrolled subjects (statin-free or statin-treated at baseline) with coronary heart disease (CHD), CHD-equivalent, or 10-year CHD risk >20%. Subjects with LDL-C between 100 to 220 mg/dL (2.6 to 5.7 mmol/L) and triglycerides ≤600 mg/dL (6.8 mmol/L) were assigned to a starting dose of atorvastatin (10 to 80 mg/d) based on LDL-C at screening. Of the 2117 subjects enrolled in ACTFAST, AIM sub-study included the 1078 statin-free patients. At study end, 85% of these subjects reached LDL-C target. Mean sFas levels were increased and sFasL were reduced in subjects at high cardiovascular risk compared with healthy subjects. Atorvastatin reduced sFas in the whole population as well as in patients with metabolic syndrome or diabetes. Minimal changes were observed in sFasL. CONCLUSIONS - sFas concentrations are increased and sFasL are decreased in subjects at high cardiovascular risk, suggesting that these proteins may be novel markers of vascular injury. Atorvastatin reduces sFas, indicating that short-term treatment with atorvastatin exhibits antiinflammatory effects in these subjects.

AB - OBJECTIVES - Increasing evidence indicates that the Fas/Fas ligand interaction is involved in atherogenesis. We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment. METHODS AND RESULTS - ACTFAST was a 12-week, prospective, multicenter, open-label trial which enrolled subjects (statin-free or statin-treated at baseline) with coronary heart disease (CHD), CHD-equivalent, or 10-year CHD risk >20%. Subjects with LDL-C between 100 to 220 mg/dL (2.6 to 5.7 mmol/L) and triglycerides ≤600 mg/dL (6.8 mmol/L) were assigned to a starting dose of atorvastatin (10 to 80 mg/d) based on LDL-C at screening. Of the 2117 subjects enrolled in ACTFAST, AIM sub-study included the 1078 statin-free patients. At study end, 85% of these subjects reached LDL-C target. Mean sFas levels were increased and sFasL were reduced in subjects at high cardiovascular risk compared with healthy subjects. Atorvastatin reduced sFas in the whole population as well as in patients with metabolic syndrome or diabetes. Minimal changes were observed in sFasL. CONCLUSIONS - sFas concentrations are increased and sFasL are decreased in subjects at high cardiovascular risk, suggesting that these proteins may be novel markers of vascular injury. Atorvastatin reduces sFas, indicating that short-term treatment with atorvastatin exhibits antiinflammatory effects in these subjects.

KW - Atorvastatin

KW - C-reactive protein

KW - Inflammation

KW - Soluble Fas

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=33847681342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847681342&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.0000250616.26308.d7

DO - 10.1161/01.ATV.0000250616.26308.d7

M3 - Article

C2 - 17053166

AN - SCOPUS:33847681342

VL - 27

SP - 168

EP - 174

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 1

ER -